Interplay of probiotics, prebiotics, synbiotics and postbiotics: a review of their therapeutic potential for gastrointestinal inflammation.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or meta-analytic pooling.
PubMed 41794479 · doi:10.1016/j.foodres.2026.118598
What was done
Narrative synthesis of recent preclinical and clinical studies examining the mechanistic interplay and therapeutic potential of prebiotics (including inulin-type fructans and galacto-oligosaccharides), probiotics, synbiotics, and postbiotics in gastrointestinal inflammatory disorders such as irritable bowel syndrome, Crohn's disease, and ulcerative colitis.
What was found
No quantitative findings or effect estimates were reported in the abstract. Qualitatively, the review describes that these biotic therapies modulate gut microbiome composition, increase short-chain fatty acid production, reinforce the intestinal barrier, and regulate immune responses to counteract dysbiosis and mucosal inflammation.
Why it matters
It consolidates current mechanistic understanding of how various biotic modalities interact to target mucosal inflammation across common inflammatory bowel and gastrointestinal conditions.
Limits
This is a narrative review with no systematic search protocol, quality assessment of included studies, or quantitative data synthesis reported in the abstract. Clinical application is constrained by high inter-individual variability in host responses, lack of standardized microbial strains, unestablished optimal dosing, and absence of a unified regulatory framework.
Cited by
- supports The gut microbiome converts prebiotic fiber into postbiotics, including short-chain fatty acids like acetate, butyrate, and propionate, and gasotransmitters.